Results 101 to 110 of about 28,958 (244)

Anticoagulation management for cardiopulmonary bypass using TEG® 6 s in a patient receiving both heparin and dabigatran

JA Clinical Reports
Background It is difficult to evaluate adequate dose of heparin for cardiopulmonary bypass (CPB) by activated clotting time (ACT) in a patient receiving both heparin and dabigatran because dabigatran can also prolong ACT.
Yu Kawada, Nobuyuki Katori, Keiko Kaji, Shoko Fujioka, Tomoki Yamaguchi   +4 more
doaj   +1 more source

Dabigatran Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation: An Evidence Based Case Report

Majalah Kardiologi Indonesia, 2013
Background. Atrial fibrillation (AF) increases the risk of having stroke as high as five fold. Anticoagulant administration such as vitamin K antagonist has been used regularly to reduce the occurence of stroke.
Alvin Nursalim, Yoga Yuniadi
doaj   +1 more source

Dabigatran etexilate [PDF]

British Journal of Clinical Pharmacology, 2010
Eline A, Dubois, Adam F, Cohen
openaire   +2 more sources

Safety and Efficacy of Minimally Interrupted Dabigatran vs Uninterrupted Warfarin Therapy in Adults Undergoing Atrial Fibrillation Catheter Ablation: A Randomized Clinical Trial.

JAMA Network Open, 2019
Importance Uninterrupted dabigatran therapy reduces stroke risk in patients with nonvalvular atrial fibrillation (NVAF) undergoing ablation and is associated with a lower bleeding risk than uninterrupted warfarin therapy.
A. Nogami, T. Harada, Y. Sekiguchi, R. Otani, Y. Yoshida, Kentaro Yoshida, Yukiko Nakano, N. Nuruki, Shiro Nakahara, M. Goya, H. Origasa, Y. Kihara, K. Hirao, K. Aonuma   +13 more
semanticscholar   +1 more source

Drug–Drug Interaction Signals for Major Bleeding in Nursing Home Residents: High‐Throughput Screening of Clopidogrel and Oral Anticoagulants

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 8, August 2026.
ABSTRACT Purpose Nursing home (NH) residents are at high risk for major bleeding and are frequently exposed to complex medication regimens that may increase the likelihood of clinically important drug–drug interactions (DDIs). However, DDI evidence from community‐dwelling populations may not generalize to NH residents, and real‐world signals involving ...
Adam M. D'Amico, Melissa R. Riester, Charles E. Leonard, Daniel A. Harris, Lori A. Daiello, Yu‐Chia (Sam) Hsu, Douglas P. Kiel, Meghan A. Cupp, Kaleen N. Hayes, Andrew R. Zullo   +9 more
wiley   +1 more source

Bioresorbable Scaffolds for Coronary Arteries: Where Do We Stand Today?

VIEW Medicine, Volume 1, Issue 1, August 2026.
Bioresorbable coronary scaffolds are moving from thick strut pitfalls to thinner, stronger, healing‐oriented designs. Integrating advances in materials, guided implantation with preparation, size, and postdilation steps, and resorption aligned to healing, we synthesize clinical evidence and chart a roadmap toward intelligent, transient platforms ...
Junya Matsuda, Tatsuya Watanabe, Satoshi Yuhara, John M. Kelly, Hirotsugu Kurobe, Toshiharu Shinoka   +5 more
wiley   +1 more source

Using Pharmacovigilance Data for Signal Detection of Drug Interactions for Rosuvastatin

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 2, August 2026.
ABSTRACT The 3‐hydroxy‐3‐methyl‐glutaryl‐coenzyme A reductase inhibitor rosuvastatin is a substrate of breast cancer resistance protein (BCRP). BCRP inhibition increases rosuvastatin plasma concentrations and may result in concentration‐dependent muscle toxicity, at worst rhabdomyolysis.
Ronja Levomäki, Päivi Hirvensalo, Aleksi Tornio, Anne M. Filppula   +3 more
wiley   +1 more source

Exploring Risks of Adverse Drug Events From Single Drug to Three‐Drug Combination

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT Use of three‐drug combinations is common and could increase the risk of adverse drug events (ADEs). Signals of ADEs from three‐drug combinations could be identified from real‐world data, and the risks of ADEs from single drug exposure to three‐drug combination exposure could be illustrated by a graphic model.
Yi Shi, Anna Sun, Chien‐Wei Chiang, Yuedi Yang, Katherine M. Hunold, Jing Xu, Mu Shan, Allison Lu, Massimiliano Russo, Jeffrey M. Caterino, Michael T. Eadon, Lang Li, Jing Su, Macarius Donneyong, Pengyue Zhang   +14 more
wiley   +1 more source

Idarucizumab for Dabigatran Reversal — Full Cohort Analysis

New England Journal of Medicine, 2017
C. Pollack, P. Reilly, J. van Ryn, J. Eikelboom, S. Glund, R. Bernstein, R. Dubiel, M. Huisman, E. Hylek, C. Kam, P. Kamphuisen, J. Kreuzer, J. Levy, G. Royle, F. Sellke, J. Stangier, T. Steiner, P. Verhamme, Bushi Wang, L. Young, J. Weitz   +20 more
semanticscholar   +2 more sources

Safety and Effectiveness of Glecaprevir/Pibrentasvir in Children and Adolescents With Chronic Hepatitis C: Reports From All‐Case Post‐Marketing Surveillance in Japan

Hepatology Research, Volume 56, Issue 8, Page 1202-1212, August 2026.
ABSTRACT Aim The aim of this all‐case post‐marketing study was to evaluate the real‐world safety and effectiveness in all children and adolescents with chronic hepatitis C with or without compensated cirrhosis treated with glecaprevir/pibrentasvir (G/P) in Japan. Methods This prospective, observational post‐marketing surveillance study was conducted at
Tatsuki Mizuochi, Katsuyoshi Kawana, Mariko Kobayashi, Eri Iwashita, Itaru Iwama, Daiki Abukawa, Hitoshi Tajiri   +6 more
wiley   +1 more source